Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC

References

• She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 2015;47(2):543–554. doi:10.3892/ijo.2015.3042
   PubMed Web of Science ®Google Scholar
• Cui DJ, Wu Y, Wen DH. CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(16):5200–5205.
   PubMed Web of Science ®Google Scholar
• Huang X, Sun L, Wen S, et al. RNA sequencing of plasma exosomes revealed novel functional long noncoding RNAs in hepatocellular carcinoma. Cancer Sci. 2020;111(9):3338–3349. doi:10.1111/cas.14516
   PubMed Web of Science ®Google Scholar
• Luo CL, Rong Y, Chen H, et al. A logistic regression model for noninvasive prediction of AFP-negative hepatocellular carcinoma. Technol Cancer Res Treat. 2019;18:1533033819846632. doi:10.1177/1533033819846632
   Web of Science ®Google Scholar
• Jing W, Peng R, Zhu M, et al. Differential expression and diagnostic significance of pre-albumin, fibrinogen combined with D-dimer in AFP-negative hepatocellular carcinoma. Pathol Oncol Res. 2020;26(3):1669–1676. doi:10.1007/s12253-019-00752-8
   PubMed Web of Science ®Google Scholar
• Li MS, Ma QL, Chen Q, et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol. 2005;11(17):2564–2569. doi:10.3748/wjg.v11.i17.2564
   PubMed Web of Science ®Google Scholar
• Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–228. doi:10.7150/ijbs.28720
   PubMed Web of Science ®Google Scholar
• Lu LH, Zhang YF, Wei W, Shi M, Guo RP. Preoperative carbohydrate antigen 19-9: its neglected role in alpha-fetoprotein-negative hepatocellular carcinoma patients. J Gastrointest Surg. 2017;21(12):2025–2032. doi:10.1007/s11605-017-3528-5
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tie C, Wang Y, et al. Upregulation of serum sphingosine (d18:1)-1-P potentially contributes to distinguish HCC including AFP-negative HCC from cirrhosis. Front Oncol. 2020;10:1759. doi:10.3389/fonc.2020.01759
   PubMed Web of Science ®Google Scholar
• Zhang N, Chen Y, Shen Y, Lou S, Deng J. Comprehensive analysis the potential biomarkers for the high-risk of childhood acute myeloid leukemia based on a competing endogenous RNA network. Blood Cells Mol Dis. 2019;79:102352. doi:10.1016/j.bcmd.2019.102352
   PubMed Web of Science ®Google Scholar
• Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–618. doi:10.1016/j.jhep.2017.04.009
   PubMed Web of Science ®Google Scholar
• Wang KC, Yang YW, Liu B, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011;472(7341):120–124. doi:10.1038/nature09819
   PubMed Web of Science ®Google Scholar
• Zhou RS, Zhang EX, Sun QF, et al. Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue. BMC Cancer. 2019;19(1):779. doi:10.1186/s12885-019-5983-8
   PubMed Web of Science ®Google Scholar
• Ba Z, Gu L, Hao S, Wang X, Cheng Z, Nie G. Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a. Cell Prolif. 2018;51(1). doi:10.1111/cpr.12409
   PubMed Web of Science ®Google Scholar
• Long J, Bai Y, Yang X, et al. Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell Int. 2019;19:90. doi:10.1186/s12935-019-0817-y
   PubMed Web of Science ®Google Scholar
• Abbastabar M, Sarfi M, Golestani A, Khalili E. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J. 2018;17:900–913.
   PubMed Web of Science ®Google Scholar
• Bai Y, Long J, Liu Z, et al. Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression. J Cell Physiol. 2019;234(10):18837–18848. doi:10.1002/jcp.28522
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qian W, Wang S, et al. Analysis of lncRNA-associated ceRNA network reveals potential lncRNA biomarkers in human colon adenocarcinoma. Cell Physiol Biochem. 2018;49(5):1778–1791. doi:10.1159/000493623
   PubMedGoogle Scholar
• Yan Y, Lu Y, Mao K, et al. Identification and validation of a prognostic four-genes signature for hepatocellular carcinoma: integrated ceRNA network analysis. Hepatol Int. 2019;13(5):618–630. doi:10.1007/s12072-019-09962-3
   PubMed Web of Science ®Google Scholar
• Guo D, Li Y, Chen Y, et al. DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway. Cell Prolif. 2019;52(4):e12628. doi:10.1111/cpr.12628
   PubMed Web of Science ®Google Scholar
• Fan J, Zhang J, Huang S, Li P. lncRNA OSER1-AS1 acts as a ceRNA to promote tumorigenesis in hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis. Biochem Biophys Res Commun. 2020;521(1):196–203. doi:10.1016/j.bbrc.2019.10.105
   PubMed Web of Science ®Google Scholar
• Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 2012;28(15):2062–2063. doi:10.1093/bioinformatics/bts344
   PubMed Web of Science ®Google Scholar
• Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–D152. doi:10.1093/nar/gku1104
   PubMed Web of Science ®Google Scholar
• Chou CH, Chang NW, Shrestha S, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44(D1):D239–D247. doi:10.1093/nar/gkv1258
   PubMed Web of Science ®Google Scholar
• Fromm B, Billipp T, Peck LE, et al. System for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome. Annu Rev Genet. 2015;49:213–242. doi:10.1146/annurev-genet-120213-092023
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808–D815. doi:10.1093/nar/gks1094
   PubMed Web of Science ®Google Scholar
• Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603. doi:10.1007/s12253-019-00585-5
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi:10.1038/s41598-017-12834-1
   PubMed Web of Science ®Google Scholar
• Wang X, Gao C, Feng F, et al. Construction and analysis of competing endogenous RNA networks for breast cancer based on TCGA dataset. Biomed Res Int. 2020;2020:4078596.
   PubMed Web of Science ®Google Scholar
• Mo M, Liu S, Ma X, et al. A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion. J Cancer Res Clin Oncol. 2019;145(8):2027–2038. doi:10.1007/s00432-019-02954-8
   PubMed Web of Science ®Google Scholar
• Chen YA, Cheng L, Zhang Y, Peng L, Yang HG. LncRNA RUSC1-AS1 promotes the proliferation of hepatocellular carcinoma cells through modulating NOTCH signaling. Neoplasma. 2020;67(6):1204–1213. doi:10.4149/neo_2020_191010N1024
   PubMed Web of Science ®Google Scholar
• Shi Y, Yang X, Xue X, et al. HANR promotes hepatocellular carcinoma progression via miR-214/EZH2/TGF-beta axis. Biochem Biophys Res Commun. 2018;506(1):189–193. doi:10.1016/j.bbrc.2018.10.038
   PubMed Web of Science ®Google Scholar
• Xu C, He T, Li Z, Liu H, Ding B. Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells. Biomed Pharmacother. 2017;95:1504–1513. doi:10.1016/j.biopha.2017.08.097
   PubMed Web of Science ®Google Scholar
• Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–641. doi:10.1002/hep.26369
   PubMed Web of Science ®Google Scholar
• Wei Q, Zhao L, Jiang L, et al. Prognostic relevance of miR-137 and its liver microenvironment regulatory target gene AFM in hepatocellular carcinoma. J Cell Physiol. 2019;234(7):11888–11899. doi:10.1002/jcp.27855
   PubMed Web of Science ®Google Scholar
• Sakabe T, Azumi J, Umekita Y, et al. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma. Liver Int. 2017;37(2):271–279. doi:10.1111/liv.13213
   PubMed Web of Science ®Google Scholar
• Xu J, Liu C, Zhou L, et al. Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev. 2012;13(2):559–562. doi:10.7314/APJCP.2012.13.2.559
   PubMedGoogle Scholar
• Zhao T, Jia L, Li J, et al. Heterogeneities of site-specific N-glycosylation in HCC tumors with low and high AFP concentrations. Front Oncol. 2020;10:496. doi:10.3389/fonc.2020.00496
   PubMed Web of Science ®Google Scholar
• Chen Z, Xiang L, Huang Y, Fang Y, Li X, Yang D. [Expression of long noncoding RNA linc00261 in hepatocellular carcinoma and its association with postoperative outcomes]. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38(10):1179–1186. Chinese.
   PubMedGoogle Scholar
• Zhang HF, Li W, Han YD. LINC00261 suppresses cell proliferation, invasion and Notch signaling pathway in hepatocellular carcinoma. Cancer Biomark. 2018;21(3):575–582. doi:10.3233/CBM-170471
   PubMed Web of Science ®Google Scholar
• Morita Y, Sakaguchi T, Ikegami K, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol. 2013;59(2):292–299. doi:10.1016/j.jhep.2013.02.030
   PubMed Web of Science ®Google Scholar
• Yang QX, Zhong S, He L, et al. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett. 2019;452:90–102. doi:10.1016/j.canlet.2019.03.028
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li Y, Hao H, et al. Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysIS. Cell Transplant. 2019;28(1_suppl):76S–86S. doi:10.1177/0963689719893950
   PubMed Web of Science ®Google Scholar
• Yue C, Ren Y, Ge H, et al. Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. Onco Targets Ther. 2019;12:561–576. doi:10.2147/OTT.S188913
   PubMed Web of Science ®Google Scholar
• Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017;29(5):375–381. doi:10.1097/CCO.0000000000000390
   PubMed Web of Science ®Google Scholar
• Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104. doi:10.1186/s13045-020-00937-8
   PubMed Web of Science ®Google Scholar
• Hussain M, Zhou Y, Song Y, et al. ATAD2 in cancer: a pharmacologically challenging but tractable target. Expert Opin Ther Targets. 2018;22(1):85–96. doi:10.1080/14728222.2018.1406921
   PubMed Web of Science ®Google Scholar